Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

What key factors are powering the surge in the chronic pruritus therapeutics market right now?

The market size of chronic pruritus therapeutics has witnessed considerable growth in the past few years. The market will expand from $10.17 billion in 2024 to $10.94 billion in 2025, marking a compound annual growth rate (CAGR) of 7.6%. This expansion during the historic period emanates from several factors such as an increase in the incidence of chronic pruritus, a surge in demand for viable treatments, climbing regulatory approvals, an upswing in product approvals, plus a rise in mergers, collaborations, and acquisitions amongst key industry players.

How fast Is the chronic pruritus therapeutics market expected to grow, and what’s its future value?

In the forthcoming years, the market size of chronic pruritus therapeutics is projected to expand significantly, reaching $14.49 billion in 2029 with a compound annual growth rate (CAGR) of 7.3%. Factors contributing to the growth during the forecast period include increasing awareness, a rise in atopic dermatitis, a greater emphasis on personalized medicine, a higher incidence of dermatological conditions, and a growing patient population. Major trends identified for the forecast period encompass the introduction of innovative medicines, the creation of novel biologics and targeted therapies, technological advancements, the blending of advanced drug delivery systems, partnerships between pharmaceutical firms and research institutions, and digital health technologies such as telemedicine.

Get your chronic pruritus therapeutics market report here!

https://www.thebusinessresearchcompany.com/report/chronic-pruritus-therapeutics-global-market-report

What are the leading drivers of growth in the chronic pruritus therapeutics market?

The chronic pruritus therapeutics market is poised for growth, propelled by the escalating occurrence of atopic dermatitis. Characterized by inflammatory symptoms such as redness, itching, dryness, and discomfort, atopic dermatitis (AD) commonly impacts those with a familial history of allergies, asthma, or hay fever. Increases in atopic dermatitis can be traced back to aspects like genetic makeup, environmental modifications, lifestyle contributors, the hygiene paradigm, heightened allergen exposure, and imbalances in skin microbiome. Therapeutics for chronic pruritus are designed to mitigate unrelenting itchiness ensuing from atopic dermatitis, by focusing on the inflammation pathways, decreasing skin irritation, and enhancing patient comfort levels. For example, data from the International Eczema Council, a nonprofit organization in the US, showed that around 223 million individuals worldwide were dealing with atopic dermatitis in 2022 (GBD 2022), which includes 43 million kids between the ages of 1-4, illustrating the condition’s notable incidence in early childhood. Consequently, the increasing occurrence of atopic dermatitis is steering the expansion of the chronic pruritus therapeutics market.

What are the key segments defining the chronic pruritus therapeutics market?

The chronic pruritus therapeutics market covered in this report is segmented –

1) By Product Type: Corticosteroid, Antihistamine, Local Anesthetic, Counterirritant, Immunosuppressant, Calcineurin Inhibitors, Other Product Types

2) By Disease Type: Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria, Other Disease Types

3) By Distribution Channel: Hospital Pharmacies, Drug stores And Retail Pharmacies, Online Providers

Subsegments:

1) By Corticosteroid: Topical Corticosteroids, Oral Corticosteroids, Injectable Corticosteroids

2) By Antihistamine: First-Generation Antihistamines, Second-Generation Antihistamines

3) By Local Anesthetic: Topical Local Anesthetics, Injectable Local Anesthetics

4) By Counterirritant: Menthol-Based Counterirritants, Camphor-Based Counterirritants

5) By Immunosuppressant: Systemic Immunosuppressants, Topical Immunosuppressants

6) By Calcineurin Inhibitors: Tacrolimus-Based Therapy, Pimecrolimus-Based Therapy

7) By Other Product Types: Biologic Therapies, Emerging Novel Therapies

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21147&type=smp

Who are the key players steering the development of the chronic pruritus therapeutics market?

Major companies operating in the chronic pruritus therapeutics market are Pfizer Incorporated, AbbVie Inc., Sanofi S.A., Novartis Aktiengesellschaft, GlaxoSmithKline plc, Toray Industries Inc., CSL Behring LLC, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Ipsen S.A., Incyte Corporation, Cipla Limited, H. Lundbeck A/S, Sumitomo Pharma Co. Ltd., Mallinckrodt Pharmaceuticals plc, Kissei Pharmaceutical Co. Ltd., Asana BioSciences LLC, Vanda Pharmaceuticals Inc., Dermavant Sciences Inc., Galderma Laboratories L.P., Cara Therapeutics Inc., Avior Bio Inc., Trevi Therapeutics Inc.

What emerging trends are influencing the growth of the chronic pruritus therapeutics market?

Within the chronic pruritus therapeutics market, dominant businesses are aiming to enhance treatment effectiveness and expedite patient relief by concentrating on the development of innovative formulations like intravenous (IV) injections. IV injections are effective in pruritus treatment as they deliver medications such as antihistamines or corticosteroids directly into the bloodstream, providing rapid itch relief and reducing inflammation. For example, in September 2023, Cara Therapeutics Inc., a U.S.-based therapeutic manufacturing firm, announced that its affiliate, Maruishi Pharmaceutical Co. Ltd, a company based in Japan, obtained approval for the Korsuva IV injection syringe, intended for pruritus treatment in hemodialysis patients, from Japan’s Ministry of Health, Labour and Welfare agency. This approval was granted following favorable Phase 3 clinical trial outcomes conducted jointly by Maruishi and Kissei Pharmaceutical Co., Ltd. This treatment demonstrated considerable enhancements in itch scores compared to a placebo, with patients tolerating it well. Following their licensing agreement with Maruishi, Cara Therapeutics, the developer of Korsuva, will now receive a milestone payment of $1.5 million, courtesy of this approval.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21147

Which regions are most influential in expanding the chronic pruritus therapeutics market?

North America was the largest region in the chronic pruritus therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic pruritus therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Autoimmune Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/autoimmune-treatment-global-market-report

PD 1 And PDL1 Inhibitors Immune Checkpoint Inhibitors Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pd-1-and-pdl1-inhibitors-or-immune-checkpoint-inhibitors-global-market-report

Pediatric Bladder Treatment Global Market Report 2025

https://thebusinessresearchcompany.com/report/pediatric-bladder-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: